碳酸锂?强的松对甲状腺功能亢进症131I治疗患者的影响

目的:研究碳酸锂?强的松应用对甲状腺功能亢进症(甲亢)患者131I治疗剂量和疗效的影响?方法:75例甲亢患者随机分为3组:对照组25例,患者仅接受131I治疗;碳酸锂组25例,患者接受131I治疗的同时口服碳酸锂0.75 g/d(从治疗前3 d至治疗后7 d);强的松组25例,患者接受131I治疗的同时口服强的松1 mg/(kg·d),后以每周5 mg逐渐减量至停用?治疗过程中根据甲状腺重量计算治疗需要的131I剂量,6个月后观察患者的治疗效果?结果:与对照组相比,碳酸锂组患者131I剂量明显减少(P < 0.05),但治疗效果无明显改善(P > 0.05);与对照组相比,强的松组患者131I治疗量有所升高,但无统计学差异(P > 0.05),而疗效却明显增加(P < 0.05)?结论:碳酸锂可以减少甲亢患者131I治疗的剂量,但对治疗效果无改善作用;强的松对131I治疗剂量无显著影响,但可以增加131I治疗甲亢的疗效?

The influence of lithium carbonate or prednisone administration on the dosage and efficacy of radioiodine treatment (131I) in hyperthyroid patients

Objective:To study the influence of lithium carbonate or prednisone administration on the dosage and efficacy of radioiodine treatment (131I) in hyperthyroid patients. Methods: Seventy five patients with primary hyperthyroidism were divided into 3 groups randomly:patients treated only with 131I(control group,n = 25),patients administered lithium carbonate in a daily dose of 0.75 g/d with 131I(lithium carbonate group,n = 25),patients took orally prednisone in an initial dose of 1 mg/kg with 131I (prednisone group,n = 25). Therapeutic doses of 131I and efficacy were observed. Results: Compared with the control group,the therapeutic dosage of 131I was reduced obviously in lithium carbonate group(P < 0.05),but curative effect had not significant improvement(P > 0.05). The therapeutic dosage of 131I for prednisone group was higher than control group,but there was no significant difference between two groups(P > 0.05),while the efficacy was improved significantly (P < 0.05). Conclusion: In patients with hyperthyroidism,lithium carbonate can reduce 131I dosage,but no improvement on the treatment effect;prednisone had no significant effect on dose of 131I therapy,but can increase the efficacy of 131I.